MedTrace Logo

Induced Pluripotent Stem Cell Derived Exosomes Nasal Drops for the Treatment of Stable Vitiligo

NCT06810869 · Status: NOT_YET_RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 29

Last updated 2025-02-06

No results posted yet for this study

Summary

Evaluate the efficacy of induced pluripotent stem cell-derived exosomes (iPSC-Exos) for the treatment of stable vitiligo

Conditions

  • Stable Vitiligo

Interventions

DRUG

human induced pluripotent stem cell derived exosomes （GD-iExo-003）

human induced pluripotent stem cell derived exosomes （GD-iExo-003）

DRUG

a placebo of exosomes derived from human induced pluripotent stem cell for injection

a placebo of exosomes derived from human induced pluripotent stem cell for injection

Sponsors & Collaborators

  • Guidon Pharmaceutics Ltd.

    collaborator INDUSTRY

  • Second Affiliated Hospital of Wannan Medical College

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-02-05
Primary Completion
2026-11-17
Completion
2026-11-17

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06810869 on ClinicalTrials.gov